157672-00-9

Usage

Uses

Used in Vaccine Development:
2(5H)-Furanone, 3-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]is used as an adjuvant in vaccine development to enhance the immune response against infectious diseases. Its immunostimulatory properties help improve the effectiveness of vaccines by promoting a stronger and longer-lasting immune response.
Used in Cancer Immunotherapy:
In cancer immunotherapy, 2(5H)-Furanone, 3-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]is used as an immunostimulant to boost the immune system's ability to recognize and attack cancer cells. By activating antigen-presenting cells, it enhances the immune response against cancer, potentially leading to improved treatment outcomes for patients.
Used in Anti-inflammatory Applications:
2(5H)-Furanone, 3-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]has been studied for its potential anti-inflammatory properties, making it a candidate for the development of new treatments for inflammatory conditions. Its ability to modulate the immune response may contribute to reducing inflammation and alleviating symptoms associated with various inflammatory diseases.
Used in Antimicrobial Applications:
The antimicrobial properties of 2(5H)-Furanone, 3-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]have also been investigated, suggesting its potential use in the development of new antimicrobial agents. Its ability to target and eliminate harmful microorganisms may contribute to the treatment of various infections and the development of novel therapeutic strategies to combat antibiotic-resistant bacteria.

Upstream product

• 157671-99-3 2-(4-fluorophenyl)-1-[2-[4-(methylsulfonyl)phenyl]-2-oxoethoxy]ethanone 
• 352-34-1 4-fluoro-1-iodobenzene 
• 64984-08-3 1-iodo-4-(methylsulfonyl)benzene 
• 35371-03-0 4-iodothioanisole 
• 104-96-1 4-methylsulfanylaniline 
• 50413-24-6 2-bromo-1-(4-methanesulfonylphenyl)ethanone 
• 1778-09-2 4-(Methylthio)acetophenone 
• 10297-73-1 4-(methanesulfonyl)acetophenone 
• 21382-98-9 p-cyanophenyl methyl sulfide 
• 121-44-8 triethylamine 
• 405-50-5 p-Fluorophenylacetic acid 
• 100-68-5 methyl-phenyl-thioether 

Downstream Products

• 1448459-12-8 (Z)-5-benzylidene-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-13-9 (Z)-5-(3-nitrobenzylidene)-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-14-0 (Z)-5-(2-methoxybenzylidene)-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-15-1 (Z)-5-(3,4,5-trimethoxybenzylidene)-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-16-2 (Z)-3-(4-fluorophenyl)-5-(furan-2-ylmethylene)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-17-3 (Z)-5-(4-hydroxy-3-methoxybenzyl idene)-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-18-4 (Z)-5-(4-hydroxybenzylidene)-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-19-5 (Z)-5-(4-bromobenzylidene)-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-20-8 (Z)-5-(4-chlorobenzylidene)-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-22-0 (Z)-5-(4-(dimethylamino)benzylidene)-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-23-1 (Z)-5-(benzo[d][1,3]dioxol-5-ylmethylene)-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-24-2 (Z)-5-(4-methoxybenzylidene)-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-25-3 (Z)-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-5-(naphthalen-1-ylmethylene)furan-2(5H)-one 
• 1448459-26-4 3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-5-(propan-2-ylidene)furan-2(5H)-one 

Relevant academic research and scientific papers

Stereoselective synthesis and anti-proliferative effects on prostate cancer evaluation of 5-substituted-3,4-diphenylfuran-2-ones

Series of 5-substituted-3,4-diphenylfuran-2-ones were stereoselectively prepared. Their potential anti-proliferative effects on prostate cancer and some of their cyclooxygenases (COXs) inhibitory activities were evaluated. Structure-activity relationship (SAR) data, acquired by substituent modification at the para-position and ortho-position of the C-3 phenyl ring and 5-substituted modification of the central furanone, showed that 3-(2-chloro-phenyl)-4-(4-methanesulfonyl-phenyl)-5-(1-methoxy-ethyl) -5H-furan-2-one (13p) was the most potent compound and could effectively reduce the proliferation of prostate cancer cells (PC3 cell IC50 = 20 μM; PC3 PCDNA cell IC50 = 5 μM; PC3 SKP2 cell IC50 = 5 μM; DU145 cell IC50 = 25 μM). The cell cycle analysis for 13p in DU145 indicated that 13p may induce G1 phase arrest.

Synthesis of18F-labelled cyclooxygenase-2 (COX-2) inhibitors via Stille reaction with 4-[18F]fluoroiodobenzene as radiotracers for positron emission tomography (PET)

The Stille reaction with 4-[18F]fluoroiodobenzene as a novel approach for the synthesis of radiotracers for monitoring COX-2 expression by means of PET has been developed. Optimized reaction conditions were elaborated by screening of various ca

Method of treating skin related conditions

A class of 3,4-diaryl substituted thiophene, derivatives and analogs thereof, pharmaceutical compositions containing them and methods of using them to treat inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: wherein Y is S; wherein X is one or two substituents selected from hydrido, halo, lower alkoxycarbonyl and carboxyl; wherein R2 and R3 are independently aryl or heteroaryl; and wherein R2 and R3 are optionally substituted with one or more radicals selected from sulfamyl, alkylsulfonyl, halo, lower alkoxy and lower alkyl; or a pharmaceutically-acceptable salt thereof.

Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use

The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent, such as, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B4 (LTB4) receptor antagonists, leukotriene A4 (LTA4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.

Phenyl heterocycles as cox-2 inhibitors

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases

The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor. Although a wide range of COX-II inhibitors may be employed but it is preferred to employ compounds of the Formula I: STR1

Method of preventing bone loss

The invention encompasses a method of inhibiting bone resorption in patients in need of such inhibition to a degree sufficient to halt or retard loss of bone mass, reduce fractures, improve bone repair and prevent or treat osteoporosis comprising: the administration of a non-toxic therapeutically effective amount of a selective cyclooxygenase-2 inhibitor such as the compounds of formula I. STR1 The invention also encompasses certain pharmaceutical compositions for the purposes described above.

Pyridyl substituted spirodienes for the treatment of inflammation

A class of substituted spirodienes is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: STR1 wherein A is selected from STR2 wherein each of R1 through R10 is independently selected from hydrido, halo, alkyl, alkoxy, alkylthio, cyano, haloalkyl, haloalkoxy, hydroxyalkyl; alkoxyalkyl, hydroxyl, mercapto, alkylsulfonyl, haloalkylsulfonyl, and sulfamyl; and wherein n is a number selected from 0, 1, 2 and 3; or a pharmaceutically-acceptable salt thereof.

Method of preparing sulfmonamides from sulfones

A one-pot synthesis of sulfonamides from sulfones has been developed. Conversion of sulfones to the corresponding sulfinic acid salts is followed by oxidative-amination to give the sulfonamides.

Substituted cyclopentenes for the treatment of inflammation

A class of 1,2-diarylcyclopentenyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula III: STR1 wherein each of R1 and R2 is independently selected from alkyl, hydrido, hydroxyalkyl, halo, haloalkyl, alkoxycarbonyl and carboxyl; wherein R5 is selected from alkylsulfonyl, haloalkylsulfonyl and sulfamyl; and wherein B is phenyl or pyridyl, wherein B is optionally substituted at a substitutable position with alkyl, halo, alkylthio, cyano, haloalkyl, alkoxy, hydroxyalkyl and alkoxyalkyl; or a pharmaceutically-acceptable salt thereof.